爱尔兰国家乳腺筛查项目召回率评估:来自两百万次筛查性乳腺X线摄影的洞见
该匿名汇总回顾性研究分析了2000至2019年间爱尔兰人群乳腺筛查项目的2,031,995次乳腺X线筛查结果,按现患与偶发检查分层描述召回率及特征。全期总召回率为4.05%(82,338/2,031,995),现患组召回率从5.5%升至8.0%再升至10.0%,偶发组从2.3%升至2.8%再升至3.0%;钙化与不对称所致召回随时间增加,钙化所致召回在现患检查中从6.0/1,000升至9.0/1,000再升至13.4/1,000(p<0.001),不对称所致召回从17.1/1,000升至31.3/1,000再升至41.0/1,000(p<0.001)。现患与偶发检查的癌症检出率均上升(分别为p=0.005和p<0.001),但总体阳性预测值保持相对稳定。
要点
- 全研究期筛查总召回率为4.05%(82,338/2,031,995)。
- 现患组召回率由5.5%升至8.0%再升至10.0%,偶发组由2.3%升至2.8%再升至3.0%。
- 钙化与不对称所致召回随时间增加,现患组钙化所致召回由6.0/1,000升至13.4/1,000(p<0.001)。
核心结论
- 研究显示爱尔兰国家乳腺筛查服务的召回率呈上升轨迹,作者指出需要包括国家和国际筛查网络在内的多元利益相关方讨论确定最佳召回率,以最大化筛查获益并最小化潜在伤害。
研究设计与样本
- 匿名汇总回顾性研究,纳入2000至2019年间2,031,995次乳腺X线筛查检查结果,按现患与偶发检查分层描述召回率及特征,并用卡方检验比较2000-2008、2009-2017和2018-2019三个时间段的差异。
诊断标准与关键数值
- 全研究期筛查检查总召回率为4.05%(n=82,338/2,031,995)。
- 现患筛查组召回率在三个时间段依次为5.5%、8.0%、10.0%,偶发组依次为2.3%、2.8%、3.0%。
- 现患检查中钙化所致召回由6.0/1,000升至9.0/1,000再升至13.4/1,000(p<0.001),不对称所致召回由17.1/1,000升至31.3/1,000再升至41.0/1,000(p<0.001)。
- 现患与偶发检查的癌症检出率均上升(分别为p=0.005和p<0.001),总体阳性预测值保持相对稳定。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Breast cancer screening aims to reduce breast cancer mortality and morbidity through early detection and treatment. Recall rate is a key performance indicator of population-based breast screening, representing the proportion of women recalled for further evaluation. Guidance on acceptable recall rates vary internationally.
AIM: To examine recall patterns and characteristics within the population-based breast screening programme in Ireland.
METHODS: An anonymous aggregate retrospective study of 2,031,995 mammography screening examination results, was conducted between 2000 and 2019. Descriptive patterns of recall rates and characteristics were examined and stratified by prevalent and incident examinations. Differences across the time-periods (2000-2008, 2009-2017 and 2018-2019) were assessed using Chi-square tests.
RESULTS: Recall rate for screening examinations conducted during the full study period was 4.05 % (n = 82,338/2,031,995). Across three time-periods examined, recall rates among the prevalent screening examination group, increased, from 5.5 % to 8.0 % to 10.0 % and within the incident group from 2.3 % to 2.8 % to 3.0 %. Recalls due to calcifications and asymmetry increased over the time periods, most notably within the prevalent examinations where recalls due to calcification increased from 6.0/1,000 to 9.0/1,000 to 13.4/1,000 (p < 0.001), whilst recalls due to asymmetry increased from 17.1/1,000 to 31.3/1,000 to 41.0/1,000 (p < 0.001). Overall, among both prevalent and incident screening examinations, an increase in the cancer detection rate (CDR) was observed (p = 0.005 and p < 0.001 respectively). However, the overall positive predictive value (PPV) remained relatively stable.
CONCLUSION: This study highlights the upward trajectory of recall within Ireland's national breast screening service. The findings highlight the need for discussions among a diverse range of stakeholders, including national and international screening networks, to determine the optimal recall rate to ensure the benefits of screening are maximised and all potential harms are minimised.
引用
- Murphy S, Mooney T, Phelan N, et al. Evaluation of recall rates in the Irish national breast screening programme: Insights from two million screening mammograms. Eur J Radiol. 2025. PMID: 40412049. doi:10.1016/j.ejrad.2025.112179
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。